South Korea Biotech Gets First Commercial Order To Clone Dog
This article was originally published in PharmAsia News
Executive Summary
RNL Bio, a biotechnology company in South Korea, now has an order to clone a pet animal as the beginning of a commercial service that could begin next year. RNL Bio is affiliated with the research laboratory of Seoul National University's stem-cell facility that produced the first cloned dog three years ago. The first commercial order for a clone came from a California woman who wants to use material from her late pit bull terrier. RNL Bio plans to charge about $150,000 per clone. (Click here for more - a subscription may be required